Francis Figaroa

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Most libraries for fragment-based drug discovery are restricted to 1,000-10,000 compounds, but over 500,000 fragments are commercially available and potentially accessible by virtual screening. Whether this larger set would increase chemotype coverage, and whether a computational screen can pragmatically prioritize them, is debated. To investigate this(More)
  • 1